Pernix Therapeutics Holdings Inc. (PTX) was one of the Russell 2000's biggest losers for Wednesday January 20 as the stock slid 9.45% to $1.82, a loss of $-0.1899 per share. Starting at an opening price of $1.97 a share, the stock traded between $1.71 and $1.97 over the course of the trading day. Volume was 1.07 million shares over 5,440 trades, against an average daily volume of 825,003 shares and a total float of 61.06 million.
The losses send Pernix Therapeutics Holdings Inc. down to a market cap of $111.13 million. In the last year, Pernix Therapeutics Holdings Inc. has traded between $12.88 and $1.91, and its 50-day SMA is currently $2.85 and 200-day SMA is $4.76.
Pernix Therapeutics Holdings Inc is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for sleep, bacterial infections and cough and cold conditions.
Pernix Therapeutics Holdings Inc. is based out of Morristown, NJ and has some 155 employees. Its CEO is Douglas Drysdale.
For a complete fundamental analysis analysis of Pernix Therapeutics Holdings Inc., check out Equities.com’s Stock Valuation Analysis report for PTX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer